BR112019023214A2 - Compostos e métodos para tratamento de dor visceral - Google Patents

Info

Publication number

BR112019023214A2

BR112019023214A2 BR112019023214-1A BR112019023214A BR112019023214A2 BR 112019023214 A2 BR112019023214 A2 BR 112019023214A2 BR 112019023214 A BR112019023214 A BR 112019023214A BR 112019023214 A2 BR112019023214 A2 BR 112019023214A2

Authority

BR

Brazil

Prior art keywords

tetrahydro

carboxylic

pentalene

compound

amide

Prior art date

2017-05-08

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 992
• 238000000034 method Methods 0.000 title claims abstract description 227
• 208000009935 visceral pain Diseases 0.000 title claims abstract description 82
• 208000002193 Pain Diseases 0.000 claims abstract description 124
• 230000036407 pain Effects 0.000 claims abstract description 119
• 208000005615 Interstitial Cystitis Diseases 0.000 claims abstract description 70
• 208000011231 Crohn disease Diseases 0.000 claims abstract description 52
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 51
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 50
• 201000007094 prostatitis Diseases 0.000 claims abstract description 36
• 238000011282 treatment Methods 0.000 claims abstract description 27
• 208000004998 Abdominal Pain Diseases 0.000 claims abstract description 22
• 208000013507 chronic prostatitis Diseases 0.000 claims abstract description 18
• 210000001835 viscera Anatomy 0.000 claims abstract description 18
• 208000000450 Pelvic Pain Diseases 0.000 claims abstract description 17
• 208000018680 Abdominal injury Diseases 0.000 claims abstract description 16
• 208000000668 Chronic Pancreatitis Diseases 0.000 claims abstract description 16
• 201000009273 Endometriosis Diseases 0.000 claims abstract description 16
• 206010033645 Pancreatitis Diseases 0.000 claims abstract description 16
• 206010033649 Pancreatitis chronic Diseases 0.000 claims abstract description 16
• 230000001684 chronic effect Effects 0.000 claims abstract description 12
• -1 ureyl Chemical group 0.000 claims description 932
• YZGJIENQZBJQNS-UHFFFAOYSA-N pentalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=C21 YZGJIENQZBJQNS-UHFFFAOYSA-N 0.000 claims description 607
• 239000002253 acid Substances 0.000 claims description 465
• 125000001072 heteroaryl group Chemical group 0.000 claims description 200
• 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 192
• 125000003118 aryl group Chemical group 0.000 claims description 189
• 125000000217 alkyl group Chemical group 0.000 claims description 159
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 151
• 125000000623 heterocyclic group Chemical group 0.000 claims description 140
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 133
• 125000001424 substituent group Chemical group 0.000 claims description 120
• 125000002947 alkylene group Chemical group 0.000 claims description 109
• 239000000203 mixture Substances 0.000 claims description 89
• 229940126062 Compound A Drugs 0.000 claims description 88
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 88
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 85
• CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims description 84
• 125000003545 alkoxy group Chemical group 0.000 claims description 83
• 229910052736 halogen Inorganic materials 0.000 claims description 75
• 150000002367 halogens Chemical class 0.000 claims description 75
• 150000003839 salts Chemical class 0.000 claims description 72
• 125000001188 haloalkyl group Chemical group 0.000 claims description 69
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 56
• 125000003282 alkyl amino group Chemical group 0.000 claims description 54
• 125000002993 cycloalkylene group Chemical group 0.000 claims description 45
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 45
• 125000005549 heteroarylene group Chemical group 0.000 claims description 45
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 44
• 125000001769 aryl amino group Chemical group 0.000 claims description 40
• 125000004104 aryloxy group Chemical group 0.000 claims description 40
• 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 40
• 150000001602 bicycloalkyls Chemical group 0.000 claims description 37
• 150000002148 esters Chemical class 0.000 claims description 34
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 33
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 25
• 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 25
• 238000000113 differential scanning calorimetry Methods 0.000 claims description 25
• 125000005553 heteroaryloxy group Chemical group 0.000 claims description 25
• 238000002411 thermogravimetry Methods 0.000 claims description 25
• 238000001757 thermogravimetry curve Methods 0.000 claims description 25
• 230000004580 weight loss Effects 0.000 claims description 25
• 239000003814 drug Substances 0.000 claims description 24
• 208000025865 Ulcer Diseases 0.000 claims description 23
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 21
• SLLXSXRRWZURNA-UHFFFAOYSA-N tricyclo[4.3.0.02,4]nona-1(9),2(4),5,7-tetraene-7-carboxylic acid Chemical compound C1=C2CC2=C2C=CC(C(=O)O)=C21 SLLXSXRRWZURNA-UHFFFAOYSA-N 0.000 claims description 21
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 20
• 125000005431 alkyl carboxamide group Chemical group 0.000 claims description 20
• 125000005129 aryl carbonyl group Chemical group 0.000 claims description 20
• 150000003857 carboxamides Chemical class 0.000 claims description 20
• 125000005363 dialkylsulfonamide group Chemical group 0.000 claims description 20
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 20
• 239000000843 powder Substances 0.000 claims description 20
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 19
• 229940079593 drug Drugs 0.000 claims description 19
• 150000001204 N-oxides Chemical class 0.000 claims description 18
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
• 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 15
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 15
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 15
• 239000004202 carbamide Substances 0.000 claims description 15
• 239000000460 chlorine Substances 0.000 claims description 15
• 229910052801 chlorine Inorganic materials 0.000 claims description 15
• 125000005724 cycloalkenylene group Chemical group 0.000 claims description 15
• 229910052731 fluorine Inorganic materials 0.000 claims description 15
• 239000011737 fluorine Substances 0.000 claims description 15
• 125000004438 haloalkoxy group Chemical group 0.000 claims description 15
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 15
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 15
• 229910052757 nitrogen Inorganic materials 0.000 claims description 15
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 15
• VEGZXOSAJZVXKI-UHFFFAOYSA-N 1-pyridin-2-ylcyclobutan-1-amine Chemical compound C=1C=CC=NC=1C1(N)CCC1 VEGZXOSAJZVXKI-UHFFFAOYSA-N 0.000 claims description 12
• 239000003937 drug carrier Substances 0.000 claims description 12
• 230000001363 autoimmune Effects 0.000 claims description 11
• 238000002512 chemotherapy Methods 0.000 claims description 11
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 11
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 11
• DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 10
• 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 claims description 10
• 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 claims description 10
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 10
• 239000013543 active substance Substances 0.000 claims description 10
• 239000002671 adjuvant Substances 0.000 claims description 10
• 229910052799 carbon Inorganic materials 0.000 claims description 10
• 239000013078 crystal Chemical group 0.000 claims description 10
• 229960004391 lorazepam Drugs 0.000 claims description 10
• YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 10
• FBWOFVFUKXZXKT-UHFFFAOYSA-N 1-(trifluoromethyl)cyclopropan-1-amine Chemical compound FC(F)(F)C1(N)CC1 FBWOFVFUKXZXKT-UHFFFAOYSA-N 0.000 claims description 9
• UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 claims description 9
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 9
• 229910052794 bromium Inorganic materials 0.000 claims description 9
• 238000002483 medication Methods 0.000 claims description 9
• 239000000014 opioid analgesic Substances 0.000 claims description 9
• 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 8
• 125000004076 pyridyl group Chemical group 0.000 claims description 8
• 230000000202 analgesic effect Effects 0.000 claims description 7
• BGTCGFXMIWDPMF-UHFFFAOYSA-N cyclopenta[c]pyrazole-3-carboxylic acid Chemical compound C1=CC=C2N=NC(C(=O)O)=C21 BGTCGFXMIWDPMF-UHFFFAOYSA-N 0.000 claims description 7
• VRDXDROAZSDMSA-UHFFFAOYSA-N (1-aminocyclobutyl)methanol Chemical compound OCC1(N)CCC1 VRDXDROAZSDMSA-UHFFFAOYSA-N 0.000 claims description 6
• 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 6
• VJRVNAHSYWCVQN-UHFFFAOYSA-N 1,1,2-trifluoro-2-methylpropan-1-amine Chemical compound CC(C)(C(N)(F)F)F VJRVNAHSYWCVQN-UHFFFAOYSA-N 0.000 claims description 6
• ZAXBVBGWLMVNJN-UHFFFAOYSA-N 1-methylcyclobutan-1-amine Chemical compound CC1(N)CCC1 ZAXBVBGWLMVNJN-UHFFFAOYSA-N 0.000 claims description 6
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 6
• OBMKZINZPBARIK-UHFFFAOYSA-N (1-aminocyclopropyl)methanol Chemical compound OCC1(N)CC1 OBMKZINZPBARIK-UHFFFAOYSA-N 0.000 claims description 5
• GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 claims description 5
• ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 5
• GNXFOGHNGIVQEH-UHFFFAOYSA-N 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 claims description 5
• KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 5
• 108030001720 Bontoxilysin Proteins 0.000 claims description 5
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 5
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 5
• 239000005977 Ethylene Substances 0.000 claims description 5
• PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 5
• KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 5
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 5
• 229960004538 alprazolam Drugs 0.000 claims description 5
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 5
• 229960000836 amitriptyline Drugs 0.000 claims description 5
• 239000000730 antalgic agent Substances 0.000 claims description 5
• 230000001773 anti-convulsant effect Effects 0.000 claims description 5
• 239000001961 anticonvulsive agent Substances 0.000 claims description 5
• 239000000935 antidepressant agent Substances 0.000 claims description 5
• 229940005513 antidepressants Drugs 0.000 claims description 5
• 239000003472 antidiabetic agent Substances 0.000 claims description 5
• 229940125708 antidiabetic agent Drugs 0.000 claims description 5
• 229960003965 antiepileptics Drugs 0.000 claims description 5
• 239000002249 anxiolytic agent Substances 0.000 claims description 5
• 229960000794 baclofen Drugs 0.000 claims description 5
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
• 229940053031 botulinum toxin Drugs 0.000 claims description 5
• 229960000623 carbamazepine Drugs 0.000 claims description 5
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 5
• JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 claims description 5
• JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 claims description 5
• 229960003572 cyclobenzaprine Drugs 0.000 claims description 5
• 229960003529 diazepam Drugs 0.000 claims description 5
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 5
• 229960002866 duloxetine Drugs 0.000 claims description 5
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 5
• 229960002870 gabapentin Drugs 0.000 claims description 5
• 230000001939 inductive effect Effects 0.000 claims description 5
• 229960001848 lamotrigine Drugs 0.000 claims description 5
• PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 5
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 5
• 229940035363 muscle relaxants Drugs 0.000 claims description 5
• 239000003158 myorelaxant agent Substances 0.000 claims description 5
• 229960001158 nortriptyline Drugs 0.000 claims description 5
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
• 229960001233 pregabalin Drugs 0.000 claims description 5
• AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 5
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 5
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 5
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
• 229960004394 topiramate Drugs 0.000 claims description 5
• PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 5
• 229960004688 venlafaxine Drugs 0.000 claims description 5
• 229960000820 zopiclone Drugs 0.000 claims description 5
• 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
• MIDTUVOKEMQNOO-UHFFFAOYSA-N 1-(fluoromethyl)cyclobutan-1-amine Chemical compound FCC1(N)CCC1 MIDTUVOKEMQNOO-UHFFFAOYSA-N 0.000 claims description 4
• KOPFEFZSAMLEHK-UHFFFAOYSA-N 1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 claims description 4
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 4
• 208000005298 acute pain Diseases 0.000 claims description 4
• 230000000007 visual effect Effects 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 3
• 238000002560 therapeutic procedure Methods 0.000 claims description 3
• WJRKNLONLOMALV-UHFFFAOYSA-N 5-chloropyridine Chemical compound ClC1=C=NC=C[CH]1 WJRKNLONLOMALV-UHFFFAOYSA-N 0.000 claims description 2
• 230000003213 activating effect Effects 0.000 claims description 2
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
• SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 16
• 238000002441 X-ray diffraction Methods 0.000 claims 10
• 229910000147 aluminium phosphate Inorganic materials 0.000 claims 9
• UYHQDFQKVUGCAQ-UHFFFAOYSA-N 1-(trifluoromethyl)cyclobutan-1-amine Chemical compound FC(F)(F)C1(N)CCC1 UYHQDFQKVUGCAQ-UHFFFAOYSA-N 0.000 claims 6
• OWKCWDNEDBFLIL-BQBZGAKWSA-N (1as,5as)-2-(pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1h-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid Chemical compound C([C@@H]1C[C@@H]1C=12)C=1C(C(=O)O)=NN2C1=CN=CC=N1 OWKCWDNEDBFLIL-BQBZGAKWSA-N 0.000 claims 3
• YRCWDUIBSJKELW-UHFFFAOYSA-N 2-fluoro-2-methylpropan-1-amine Chemical compound CC(C)(F)CN YRCWDUIBSJKELW-UHFFFAOYSA-N 0.000 claims 3
• 125000006343 heptafluoro propyl group Chemical group 0.000 claims 3
• LPEUUBBXMBUTCQ-UHFFFAOYSA-N 2-amino-3-fluoro-2-(fluoromethyl)propan-1-ol Chemical compound OCC(N)(CF)CF LPEUUBBXMBUTCQ-UHFFFAOYSA-N 0.000 claims 2
• QNQLEPMSOYMGIQ-UHFFFAOYSA-N N-tert-butylpentalene-1-carboxamide Chemical compound C(C)(C)(C)NC(=O)C=1C2=CC=CC2=CC=1 QNQLEPMSOYMGIQ-UHFFFAOYSA-N 0.000 claims 2
• 230000000949 anxiolytic effect Effects 0.000 claims 2
• ZQLKHPNBHSTSIE-UHFFFAOYSA-N dimethoxy carbonate Chemical compound COOC(=O)OOC ZQLKHPNBHSTSIE-UHFFFAOYSA-N 0.000 claims 2
• 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
• 201000003146 cystitis Diseases 0.000 claims 1
• 201000010063 epididymitis Diseases 0.000 abstract description 4
• 206010005063 Bladder pain Diseases 0.000 abstract description 2
• 238000009802 hysterectomy Methods 0.000 abstract description 2
• 238000009806 oophorectomy Methods 0.000 abstract description 2
• 238000002271 resection Methods 0.000 abstract description 2
• DNJYDNMEAKYPAZ-UHFFFAOYSA-N N1C=2C1=CC1=C(C=NC=21)C(=O)O Chemical compound N1C=2C1=CC1=C(C=NC=21)C(=O)O DNJYDNMEAKYPAZ-UHFFFAOYSA-N 0.000 description 24
• 238000002360 preparation method Methods 0.000 description 21
• 230000000694 effects Effects 0.000 description 20
• KDFDOINBXBEOLZ-UHFFFAOYSA-N 2-phenylpropan-2-amine Chemical compound CC(C)(N)C1=CC=CC=C1 KDFDOINBXBEOLZ-UHFFFAOYSA-N 0.000 description 17
• 239000003981 vehicle Substances 0.000 description 17
• 239000003826 tablet Substances 0.000 description 16
• 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 15
• 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 15
• 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 15
• 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 15
• 238000000634 powder X-ray diffraction Methods 0.000 description 15
• 241000700159 Rattus Species 0.000 description 14
• 150000004702 methyl esters Chemical class 0.000 description 13
• 239000000243 solution Substances 0.000 description 13
• 239000007788 liquid Substances 0.000 description 12
• 208000004454 Hyperalgesia Diseases 0.000 description 11
• 239000002775 capsule Substances 0.000 description 11
• IPBPLHNLRKRLPJ-UHFFFAOYSA-N oxan-4-ylmethanamine Chemical compound NCC1CCOCC1 IPBPLHNLRKRLPJ-UHFFFAOYSA-N 0.000 description 11
• 239000007787 solid Substances 0.000 description 11
• 239000000556 agonist Substances 0.000 description 10
• 239000002552 dosage form Substances 0.000 description 10
• CHODSSFYKUSDHG-UHFFFAOYSA-N 1-fluoro-2-methylpropan-2-amine Chemical compound CC(C)(N)CF CHODSSFYKUSDHG-UHFFFAOYSA-N 0.000 description 9
• IDWHILRTFFJHIU-UHFFFAOYSA-N 1-pyridin-4-ylcyclobutan-1-amine Chemical compound C=1C=NC=CC=1C1(N)CCC1 IDWHILRTFFJHIU-UHFFFAOYSA-N 0.000 description 9
• 239000004480 active ingredient Substances 0.000 description 9
• 230000001154 acute effect Effects 0.000 description 9
• 239000002904 solvent Substances 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• 208000035154 Hyperesthesia Diseases 0.000 description 8
• 229930003827 cannabinoid Natural products 0.000 description 8
• 239000003557 cannabinoid Substances 0.000 description 8
• JQULXIOYDDCNGR-UHFFFAOYSA-N 2-amino-2-methylpropanenitrile Chemical compound CC(C)(N)C#N JQULXIOYDDCNGR-UHFFFAOYSA-N 0.000 description 7
• 201000010099 disease Diseases 0.000 description 7
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
• 208000004296 neuralgia Diseases 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• OYRBDGKUVUVWRI-UHFFFAOYSA-N 1-phenylcyclopropan-1-amine Chemical compound C=1C=CC=CC=1C1(N)CC1 OYRBDGKUVUVWRI-UHFFFAOYSA-N 0.000 description 6
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 229940065144 cannabinoids Drugs 0.000 description 6
• 208000021722 neuropathic pain Diseases 0.000 description 6
• 238000011321 prophylaxis Methods 0.000 description 6
• 241000282414 Homo sapiens Species 0.000 description 5
• 206010065390 Inflammatory pain Diseases 0.000 description 5
• 150000001408 amides Chemical class 0.000 description 5
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 5
• 230000006378 damage Effects 0.000 description 5
• 239000000839 emulsion Substances 0.000 description 5
• 239000012453 solvate Substances 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 239000000375 suspending agent Substances 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• XOJUNYXOESDYTH-SSDOTTSWSA-N (2S)-2-amino-2-(oxan-4-yl)ethanol Chemical compound OC[C@@H](N)C1CCOCC1 XOJUNYXOESDYTH-SSDOTTSWSA-N 0.000 description 4
• YFBWGBFWVFEGEZ-UHFFFAOYSA-N 1,1,1-trifluoro-2-methylpropan-2-amine Chemical compound CC(C)(N)C(F)(F)F YFBWGBFWVFEGEZ-UHFFFAOYSA-N 0.000 description 4
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 4
• YJTXQLYMECWULH-UHFFFAOYSA-N 5-fluoropyridin-2-amine Chemical compound NC1=CC=C(F)C=N1 YJTXQLYMECWULH-UHFFFAOYSA-N 0.000 description 4
• BOCGDVQHSNBYCF-UHFFFAOYSA-N C1=C2CC2C2NNC(C(=O)O)=C21 Chemical compound C1=C2CC2C2NNC(C(=O)O)=C21 BOCGDVQHSNBYCF-UHFFFAOYSA-N 0.000 description 4
• 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 4
• 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 4
• 206010020751 Hypersensitivity Diseases 0.000 description 4
• 208000027418 Wounds and injury Diseases 0.000 description 4
• 230000036760 body temperature Effects 0.000 description 4
• 239000003556 cannabinoid 2 receptor agonist Substances 0.000 description 4
• YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
• 239000000796 flavoring agent Substances 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 208000014674 injury Diseases 0.000 description 4
• 230000006742 locomotor activity Effects 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 229920000609 methyl cellulose Polymers 0.000 description 4
• 239000001923 methylcellulose Substances 0.000 description 4
• 235000010981 methylcellulose Nutrition 0.000 description 4
• 210000000929 nociceptor Anatomy 0.000 description 4
• 230000002093 peripheral effect Effects 0.000 description 4
• 150000003014 phosphoric acid esters Chemical class 0.000 description 4
• 239000006187 pill Substances 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• GICNBHGJGXBSBL-UHFFFAOYSA-N (4-aminooxan-4-yl)methanol Chemical compound OCC1(N)CCOCC1 GICNBHGJGXBSBL-UHFFFAOYSA-N 0.000 description 3
• JZDJCPUJSHPOJP-UHFFFAOYSA-N 1-(4-fluorophenyl)cyclopropan-1-amine Chemical compound C=1C=C(F)C=CC=1C1(N)CC1 JZDJCPUJSHPOJP-UHFFFAOYSA-N 0.000 description 3
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 3
• ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 3
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 3
• RGDQRXPEZUNWHX-UHFFFAOYSA-N 3-methylpyridin-2-amine Chemical compound CC1=CC=CN=C1N RGDQRXPEZUNWHX-UHFFFAOYSA-N 0.000 description 3
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 3
• 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 3
• IBCDZSNPILGMEF-UHFFFAOYSA-N 8,9-diazatricyclo[4.3.0.02,4]nona-1(9),2(4),5,7-tetraene-7-carboxylic acid Chemical compound C1=C2CC2=C2N=NC(C(=O)O)=C21 IBCDZSNPILGMEF-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 229920002261 Corn starch Polymers 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 150000001200 N-acyl ethanolamides Chemical class 0.000 description 3
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
• 208000026935 allergic disease Diseases 0.000 description 3
• 206010053552 allodynia Diseases 0.000 description 3
• 230000000049 anti-anxiety effect Effects 0.000 description 3
• 230000027455 binding Effects 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 239000001768 carboxy methyl cellulose Substances 0.000 description 3
• 210000004027 cell Anatomy 0.000 description 3
• 230000001149 cognitive effect Effects 0.000 description 3
• 239000008120 corn starch Substances 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000002270 dispersing agent Substances 0.000 description 3
• 239000002621 endocannabinoid Substances 0.000 description 3
• 235000019634 flavors Nutrition 0.000 description 3
• 230000009610 hypersensitivity Effects 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 239000007937 lozenge Substances 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 229910052751 metal Inorganic materials 0.000 description 3
• 239000002184 metal Substances 0.000 description 3
• WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 3
• 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• 210000003932 urinary bladder Anatomy 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• TXPRFSOGPYITOT-UHFFFAOYSA-N (6-aminopyridin-3-yl)methanol Chemical compound NC1=CC=C(CO)C=N1 TXPRFSOGPYITOT-UHFFFAOYSA-N 0.000 description 2
• SSNHGLKFJISNTR-DYSNNVSPSA-N (6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol Chemical class OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1.C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 SSNHGLKFJISNTR-DYSNNVSPSA-N 0.000 description 2
• AXNNZTURGGNMJF-UHFFFAOYSA-N 1-(2-fluorophenyl)cyclobutan-1-amine Chemical compound C=1C=CC=C(F)C=1C1(N)CCC1 AXNNZTURGGNMJF-UHFFFAOYSA-N 0.000 description 2
• OLNNGMGXTFSLEW-UHFFFAOYSA-N 1-(2-methoxyphenyl)cyclopropan-1-amine Chemical compound COC1=CC=CC=C1C1(N)CC1 OLNNGMGXTFSLEW-UHFFFAOYSA-N 0.000 description 2
• HRVLXTZHPZXHTR-UHFFFAOYSA-N 1-pyridin-2-ylcyclopropan-1-amine Chemical compound C=1C=CC=NC=1C1(N)CC1 HRVLXTZHPZXHTR-UHFFFAOYSA-N 0.000 description 2
• OUHQNKPDMOMQIH-UHFFFAOYSA-N 2,2-dimethyl-1-pyridin-2-ylpropan-1-amine Chemical compound CC(C)(C)C(N)C1=CC=CC=N1 OUHQNKPDMOMQIH-UHFFFAOYSA-N 0.000 description 2
• HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical compound NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 description 2
• BYHDMZFKZJRAOH-UHFFFAOYSA-N 2-amino-2-(oxolan-3-yl)ethanol Chemical compound OCC(N)C1CCOC1 BYHDMZFKZJRAOH-UHFFFAOYSA-N 0.000 description 2
• DQSQBZXDMHDHEO-UHFFFAOYSA-N 2-pyridin-2-ylpropan-2-amine Chemical compound CC(C)(N)C1=CC=CC=N1 DQSQBZXDMHDHEO-UHFFFAOYSA-N 0.000 description 2
• RBODGSBXYRGECX-UHFFFAOYSA-N 2-pyridin-4-ylpropan-2-amine Chemical compound CC(C)(N)C1=CC=NC=C1 RBODGSBXYRGECX-UHFFFAOYSA-N 0.000 description 2
• BRBUBVKGJRPRRD-UHFFFAOYSA-N 4,6-dimethylpyridin-2-amine Chemical compound CC1=CC(C)=NC(N)=C1 BRBUBVKGJRPRRD-UHFFFAOYSA-N 0.000 description 2
• VYZUBHRSGQAROM-UHFFFAOYSA-N 5-fluoro-2-methoxyaniline Chemical compound COC1=CC=C(F)C=C1N VYZUBHRSGQAROM-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• 208000030090 Acute Disease Diseases 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 241000218236 Cannabis Species 0.000 description 2
• 208000017667 Chronic Disease Diseases 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 101000600766 Homo sapiens Podoplanin Proteins 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 102100037265 Podoplanin Human genes 0.000 description 2
• 208000004550 Postoperative Pain Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• WEXNUMMSIPWAEW-UHFFFAOYSA-N [1-(3,3,3-trifluoropropyl)piperidin-4-yl]methanamine Chemical compound NCC1CCN(CCC(F)(F)F)CC1 WEXNUMMSIPWAEW-UHFFFAOYSA-N 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 239000003554 cannabinoid 1 receptor agonist Substances 0.000 description 2
• 235000017663 capsaicin Nutrition 0.000 description 2
• 229960002504 capsaicin Drugs 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 206010009887 colitis Diseases 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 238000013213 extrapolation Methods 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 230000001965 increasing effect Effects 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 229940005483 opioid analgesics Drugs 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 2
• 239000006201 parenteral dosage form Substances 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
• XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 2
• 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 210000001032 spinal nerve Anatomy 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
• 229960001052 streptozocin Drugs 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 239000002562 thickening agent Substances 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• OCEFQMDRSTWAKW-UHFFFAOYSA-N (1,4-dimethylpyrrol-2-yl)methanamine Chemical compound CC=1C=C(CN)N(C)C=1 OCEFQMDRSTWAKW-UHFFFAOYSA-N 0.000 description 1
• VDPLLINNMXFNQX-UHFFFAOYSA-N (1-aminocyclohexyl)methanol Chemical compound OCC1(N)CCCCC1 VDPLLINNMXFNQX-UHFFFAOYSA-N 0.000 description 1
• AGTPSAZJSOQXHJ-UHFFFAOYSA-N (1-methylpiperidin-4-yl)methanamine Chemical compound CN1CCC(CN)CC1 AGTPSAZJSOQXHJ-UHFFFAOYSA-N 0.000 description 1
• JNCPKKGFSCOURD-UHFFFAOYSA-N (1-morpholin-4-ylcyclopentyl)methanamine Chemical compound C1COCCN1C1(CN)CCCC1 JNCPKKGFSCOURD-UHFFFAOYSA-N 0.000 description 1
• RDWGGRZPPAFBSK-UHFFFAOYSA-N (1-pyridin-2-ylcyclobutyl)methanamine Chemical compound C=1C=CC=NC=1C1(CN)CCC1 RDWGGRZPPAFBSK-UHFFFAOYSA-N 0.000 description 1
• ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
• UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
• WPRXXGZKFVDYPB-SECBINFHSA-N (1S)-1-(5-fluoropyridin-2-yl)-2,2-dimethylpropan-1-amine Chemical compound CC(C)(C)[C@H](N)C1=CC=C(F)C=N1 WPRXXGZKFVDYPB-SECBINFHSA-N 0.000 description 1
• AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
• ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
• XJEVHMGJSYVQBQ-VIFPVBQESA-N (1s)-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2[C@@H](N)CCC2=C1 XJEVHMGJSYVQBQ-VIFPVBQESA-N 0.000 description 1
• GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
• SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
• LVMPWFJVYMXSNY-UHFFFAOYSA-N (2,3-dimethoxyphenyl)methanamine Chemical compound COC1=CC=CC(CN)=C1OC LVMPWFJVYMXSNY-UHFFFAOYSA-N 0.000 description 1
• UKLRWOHZBISUMI-UHFFFAOYSA-N (2,3-dimethylphenyl)methanamine Chemical compound CC1=CC=CC(CN)=C1C UKLRWOHZBISUMI-UHFFFAOYSA-N 0.000 description 1
• OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
• QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
• GDFBHCMFIUBEQT-UHFFFAOYSA-N (2,5-difluorophenyl)methanamine Chemical compound NCC1=CC(F)=CC=C1F GDFBHCMFIUBEQT-UHFFFAOYSA-N 0.000 description 1
• LUJNPFWZXIGIPS-UHFFFAOYSA-N (2,5-dimethylphenyl)methanamine Chemical compound CC1=CC=C(C)C(CN)=C1 LUJNPFWZXIGIPS-UHFFFAOYSA-N 0.000 description 1
• ZRJJXXDQIQFZBW-UHFFFAOYSA-N (2-aminopyridin-4-yl)methanol Chemical compound NC1=CC(CO)=CC=N1 ZRJJXXDQIQFZBW-UHFFFAOYSA-N 0.000 description 1
• PXJACNDVRNAFHD-UHFFFAOYSA-N (2-methoxyphenyl)methanamine Chemical compound COC1=CC=CC=C1CN PXJACNDVRNAFHD-UHFFFAOYSA-N 0.000 description 1
• CPKFEQXFJKNNID-RXMQYKEDSA-N (2S)-2-amino-3,3-dimethyl-N-(2,2,2-trifluoroethyl)butanamide Chemical compound CC(C)(C)[C@H](N)C(=O)NCC(F)(F)F CPKFEQXFJKNNID-RXMQYKEDSA-N 0.000 description 1
• GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
• GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
• IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
• YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
• VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
• WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
• STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
• GRRIMVWABNHKBX-UHFFFAOYSA-N (3-methoxyphenyl)methanamine Chemical compound COC1=CC=CC(CN)=C1 GRRIMVWABNHKBX-UHFFFAOYSA-N 0.000 description 1
• DXKXCEYSOXUATJ-QMMMGPOBSA-N (3S)-1-(2-methoxyethyl)piperidin-3-amine Chemical compound COCCN1CCC[C@H](N)C1 DXKXCEYSOXUATJ-QMMMGPOBSA-N 0.000 description 1
• QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
• FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
• IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
• UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
• OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
• HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
• MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
• SRWRVWNAMHIATJ-ZETCQYMHSA-N (3s)-1-(2-methoxyethyl)pyrrolidin-3-amine Chemical compound COCCN1CC[C@H](N)C1 SRWRVWNAMHIATJ-ZETCQYMHSA-N 0.000 description 1
• CKZVBXBEDDAEFE-UHFFFAOYSA-N (4-benzylmorpholin-2-yl)methanamine Chemical compound C1COC(CN)CN1CC1=CC=CC=C1 CKZVBXBEDDAEFE-UHFFFAOYSA-N 0.000 description 1
• SOBFKNVNVLNAJQ-UHFFFAOYSA-N (4-methylmorpholin-2-yl)methanamine Chemical compound CN1CCOC(CN)C1 SOBFKNVNVLNAJQ-UHFFFAOYSA-N 0.000 description 1
• YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
• STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
• MPBCUCGKHDEUDD-UHFFFAOYSA-N (5-methylpyrazin-2-yl)methanamine Chemical compound CC1=CN=C(CN)C=N1 MPBCUCGKHDEUDD-UHFFFAOYSA-N 0.000 description 1
• OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 1
• NZPFQOXRHLUPRT-UHFFFAOYSA-N (6-methylpyridin-3-yl)methanamine Chemical compound CC1=CC=C(CN)C=N1 NZPFQOXRHLUPRT-UHFFFAOYSA-N 0.000 description 1
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
• YZNQLDLXHVMJJA-UHFFFAOYSA-N 1,1-bis(4-chlorophenyl)prop-2-yn-1-ol Chemical compound C=1C=C(Cl)C=CC=1C(C#C)(O)C1=CC=C(Cl)C=C1 YZNQLDLXHVMJJA-UHFFFAOYSA-N 0.000 description 1
• CGXOAAMIQPDTPE-UHFFFAOYSA-N 1,2,2,6,6-pentamethylpiperidin-4-amine Chemical compound CN1C(C)(C)CC(N)CC1(C)C CGXOAAMIQPDTPE-UHFFFAOYSA-N 0.000 description 1
• CQNSOIKACZHLHP-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinolin-2-ium-7-carboxylate Chemical compound C1CNCC2=CC(C(=O)O)=CC=C21 CQNSOIKACZHLHP-UHFFFAOYSA-N 0.000 description 1
• ZILSBZLQGRBMOR-UHFFFAOYSA-N 1,3-benzodioxol-5-ylmethanamine Chemical compound NCC1=CC=C2OCOC2=C1 ZILSBZLQGRBMOR-UHFFFAOYSA-N 0.000 description 1
• JPBLHOJFMBOCAF-UHFFFAOYSA-N 1,3-benzoxazol-2-amine Chemical compound C1=CC=C2OC(N)=NC2=C1 JPBLHOJFMBOCAF-UHFFFAOYSA-N 0.000 description 1
• DSZCUJHVOLGWBO-UHFFFAOYSA-N 1,3-dimethoxypropan-2-amine Chemical compound COCC(N)COC DSZCUJHVOLGWBO-UHFFFAOYSA-N 0.000 description 1
• KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
• PMUHZJKXCBFDEV-UHFFFAOYSA-N 1-(2-fluorophenyl)cyclopropan-1-amine Chemical compound C=1C=CC=C(F)C=1C1(N)CC1 PMUHZJKXCBFDEV-UHFFFAOYSA-N 0.000 description 1
• CFAUIGXZAZTKLS-UHFFFAOYSA-N 1-(2-methoxyethyl)azetidin-3-amine Chemical compound COCCN1CC(N)C1 CFAUIGXZAZTKLS-UHFFFAOYSA-N 0.000 description 1
• ILMDRDDKNWKCNX-UHFFFAOYSA-N 1-(2-methoxyethyl)piperidin-4-amine Chemical compound COCCN1CCC(N)CC1 ILMDRDDKNWKCNX-UHFFFAOYSA-N 0.000 description 1
• SLAOJCJLHUAWQS-UHFFFAOYSA-N 1-(3,3,3-trifluoropropyl)azetidin-3-amine Chemical compound NC1CN(CCC(F)(F)F)C1 SLAOJCJLHUAWQS-UHFFFAOYSA-N 0.000 description 1
• RXMBVCSHXNOZCE-UHFFFAOYSA-N 1-(3,3,3-trifluoropropyl)piperidin-4-amine Chemical compound NC1CCN(CCC(F)(F)F)CC1 RXMBVCSHXNOZCE-UHFFFAOYSA-N 0.000 description 1
• QSYUGDFRPMSYOD-UHFFFAOYSA-N 1-(3-fluorophenyl)cyclobutan-1-amine Chemical compound C=1C=CC(F)=CC=1C1(N)CCC1 QSYUGDFRPMSYOD-UHFFFAOYSA-N 0.000 description 1
• QVTZALHUUXQDTQ-UHFFFAOYSA-N 1-(3-fluorophenyl)cyclopropan-1-amine Chemical compound C=1C=CC(F)=CC=1C1(N)CC1 QVTZALHUUXQDTQ-UHFFFAOYSA-N 0.000 description 1
• PPKMJRHXTNEBGP-UHFFFAOYSA-N 1-(3-methoxyphenyl)cyclobutan-1-amine Chemical compound COC1=CC=CC(C2(N)CCC2)=C1 PPKMJRHXTNEBGP-UHFFFAOYSA-N 0.000 description 1
• QOUFBHVWPGAWAG-UHFFFAOYSA-N 1-(3-methoxyphenyl)cyclopropan-1-amine Chemical compound COC1=CC=CC(C2(N)CC2)=C1 QOUFBHVWPGAWAG-UHFFFAOYSA-N 0.000 description 1
• QAPBZJDWGYFMAS-UHFFFAOYSA-N 1-(3-methylphenyl)cyclopropan-1-amine Chemical compound CC1=CC=CC(C2(N)CC2)=C1 QAPBZJDWGYFMAS-UHFFFAOYSA-N 0.000 description 1
• BIUYXIXKGQWDNE-UHFFFAOYSA-N 1-(4-chlorophenyl)cyclobutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1(N)CCC1 BIUYXIXKGQWDNE-UHFFFAOYSA-N 0.000 description 1
• PAPAYUQUJVLXAF-UHFFFAOYSA-N 1-(4-fluorophenyl)cyclobutan-1-amine Chemical compound C=1C=C(F)C=CC=1C1(N)CCC1 PAPAYUQUJVLXAF-UHFFFAOYSA-N 0.000 description 1
• LHPLFXKYTQGLLU-UHFFFAOYSA-N 1-(4-methoxyphenyl)cyclobutan-1-amine Chemical compound C1=CC(OC)=CC=C1C1(N)CCC1 LHPLFXKYTQGLLU-UHFFFAOYSA-N 0.000 description 1
• ANCAJMAPVNINSB-UHFFFAOYSA-N 1-(4-methoxyphenyl)cyclopropan-1-amine Chemical compound C1=CC(OC)=CC=C1C1(N)CC1 ANCAJMAPVNINSB-UHFFFAOYSA-N 0.000 description 1
• IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
• WPRXXGZKFVDYPB-UHFFFAOYSA-N 1-(5-fluoropyridin-2-yl)-2,2-dimethylpropan-1-amine Chemical compound CC(C)(C)C(N)C1=CC=C(F)C=N1 WPRXXGZKFVDYPB-UHFFFAOYSA-N 0.000 description 1
• WYWLBJSLKUQLHT-UHFFFAOYSA-N 1-(6-methylpyridin-2-yl)ethanamine Chemical compound CC(N)C1=CC=CC(C)=N1 WYWLBJSLKUQLHT-UHFFFAOYSA-N 0.000 description 1
• KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
• WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
• ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
• DTLMAVRNDURROY-UHFFFAOYSA-N 1-amino-2-methylcyclopropan-1-ol Chemical compound NC1(C(C1)C)O DTLMAVRNDURROY-UHFFFAOYSA-N 0.000 description 1
• QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
• CKIBVKFNWYPTKJ-UHFFFAOYSA-N 1-amino-N-pyridin-2-ylcyclobutane-1-carboxamide Chemical compound C=1C=CC=NC=1NC(=O)C1(N)CCC1 CKIBVKFNWYPTKJ-UHFFFAOYSA-N 0.000 description 1
• SILFUQGFSMYYME-UHFFFAOYSA-N 1-aminocyclobutane-1-carboxamide Chemical compound NC(=O)C1(N)CCC1 SILFUQGFSMYYME-UHFFFAOYSA-N 0.000 description 1
• HUMMCZRNZCKXHL-UHFFFAOYSA-N 1-aminocyclohexane-1-carbonitrile Chemical compound N#CC1(N)CCCCC1 HUMMCZRNZCKXHL-UHFFFAOYSA-N 0.000 description 1
• OMGAOBAAEGMMTF-UHFFFAOYSA-N 1-methyl-3,4-dihydro-2h-quinolin-7-amine Chemical compound C1=C(N)C=C2N(C)CCCC2=C1 OMGAOBAAEGMMTF-UHFFFAOYSA-N 0.000 description 1
• VSRXAWSAKJABKW-UHFFFAOYSA-N 1-methylcyclopropan-1-amine Chemical compound CC1(N)CC1 VSRXAWSAKJABKW-UHFFFAOYSA-N 0.000 description 1
• GOMKSDWWSUWVOG-UHFFFAOYSA-N 1-pyridin-4-ylcyclopropan-1-amine Chemical compound C=1C=NC=CC=1C1(N)CC1 GOMKSDWWSUWVOG-UHFFFAOYSA-N 0.000 description 1
• SVPKNMBRVBMTLB-UHFFFAOYSA-N 2,3-dichloronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(Cl)=C(Cl)C(=O)C2=C1 SVPKNMBRVBMTLB-UHFFFAOYSA-N 0.000 description 1
• NAZDVUBIEPVUKE-UHFFFAOYSA-N 2,5-dimethoxyaniline Chemical compound COC1=CC=C(OC)C(N)=C1 NAZDVUBIEPVUKE-UHFFFAOYSA-N 0.000 description 1
• OQLYLAOKFUUBBI-UHFFFAOYSA-N 2,5-dimethylpyridin-3-amine Chemical compound CC1=CN=C(C)C(N)=C1 OQLYLAOKFUUBBI-UHFFFAOYSA-N 0.000 description 1
• WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
• BJJDXAFKCKSLTE-UHFFFAOYSA-N 2,6-dimethylpyrimidin-4-amine Chemical compound CC1=CC(N)=NC(C)=N1 BJJDXAFKCKSLTE-UHFFFAOYSA-N 0.000 description 1
• FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
• OTOBTLZVXNJQAW-UHFFFAOYSA-N 2-(2,6-dimethylmorpholin-4-yl)-2-methylpropan-1-amine Chemical compound CC1CN(C(C)(C)CN)CC(C)O1 OTOBTLZVXNJQAW-UHFFFAOYSA-N 0.000 description 1
• VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
• QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
• RZBOMSOHMOVUES-UHFFFAOYSA-N 2-(2-chlorophenyl)ethanamine Chemical compound NCCC1=CC=CC=C1Cl RZBOMSOHMOVUES-UHFFFAOYSA-N 0.000 description 1
• HTMIRIIZZGJJBK-UHFFFAOYSA-N 2-(4-fluorophenoxy)ethanamine Chemical compound NCCOC1=CC=C(F)C=C1 HTMIRIIZZGJJBK-UHFFFAOYSA-N 0.000 description 1
• MMSHDAHNUHLXQD-UHFFFAOYSA-N 2-(aminomethyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1CN MMSHDAHNUHLXQD-UHFFFAOYSA-N 0.000 description 1
• KPRZOPQOBJRYSW-UHFFFAOYSA-N 2-(aminomethyl)phenol Chemical compound NCC1=CC=CC=C1O KPRZOPQOBJRYSW-UHFFFAOYSA-N 0.000 description 1
• YNZFFALZMRAPHQ-SYYKKAFVSA-N 2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol Chemical compound OC1=CC(C(C)(C)CCCCCC)=CC=C1[C@H]1[C@H](CCCO)CC[C@@H](O)C1 YNZFFALZMRAPHQ-SYYKKAFVSA-N 0.000 description 1
• MDFXJBQEWLCGHP-MFOYZWKCSA-N 2-[2-[(z)-(pyridine-4-carbonylhydrazinylidene)methyl]phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=CC=C1\C=N/NC(=O)C1=CC=NC=C1 MDFXJBQEWLCGHP-MFOYZWKCSA-N 0.000 description 1
• PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
• FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
• PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
• HPDPVPUXPBZBOJ-UHFFFAOYSA-N 2-[chloro(difluoro)methoxy]-1,1,1-trifluoroethane Chemical compound FC(F)(F)COC(F)(F)Cl HPDPVPUXPBZBOJ-UHFFFAOYSA-N 0.000 description 1
• VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
• BTKNUYMZBBWHIM-UHFFFAOYSA-N 2-amino-1-pyridin-3-ylethanol Chemical compound NCC(O)C1=CC=CN=C1 BTKNUYMZBBWHIM-UHFFFAOYSA-N 0.000 description 1
• XYIUAYKSHAYZDY-UHFFFAOYSA-N 2-amino-1-pyridin-4-ylethanol Chemical compound NCC(O)C1=CC=NC=C1 XYIUAYKSHAYZDY-UHFFFAOYSA-N 0.000 description 1
• XOJUNYXOESDYTH-UHFFFAOYSA-N 2-amino-2-(oxan-4-yl)ethanol Chemical compound OCC(N)C1CCOCC1 XOJUNYXOESDYTH-UHFFFAOYSA-N 0.000 description 1
• ULDFRPKVIZMKJG-UHFFFAOYSA-N 2-amino-4-fluorophenol Chemical compound NC1=CC(F)=CC=C1O ULDFRPKVIZMKJG-UHFFFAOYSA-N 0.000 description 1
• YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
• TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
• RNHNYMFWMMPSSH-UHFFFAOYSA-N 2-amino-N-methyl-2-pyridin-2-ylacetamide Chemical compound CNC(=O)C(N)C1=CC=CC=N1 RNHNYMFWMMPSSH-UHFFFAOYSA-N 0.000 description 1
• HEZDWTXSXRFPEP-UHFFFAOYSA-N 2-amino-n,2-dimethylpropanamide Chemical compound CNC(=O)C(C)(C)N HEZDWTXSXRFPEP-UHFFFAOYSA-N 0.000 description 1
• JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 1
• KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 1
• MEQBJJUWDCYIAB-UHFFFAOYSA-N 2-chloropyridin-3-amine Chemical compound NC1=CC=CN=C1Cl MEQBJJUWDCYIAB-UHFFFAOYSA-N 0.000 description 1
• UGUIBNHHDIEZJI-UHFFFAOYSA-N 2-fluoro-4-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=C(N)C(F)=C1 UGUIBNHHDIEZJI-UHFFFAOYSA-N 0.000 description 1
• QVDACIZNNNFTBO-UHFFFAOYSA-N 2-fluoropyridin-3-amine Chemical compound NC1=CC=CN=C1F QVDACIZNNNFTBO-UHFFFAOYSA-N 0.000 description 1
• LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
• ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
• SVEQHRSELNPKJJ-UHFFFAOYSA-N 2-methoxypyridin-4-amine Chemical compound COC1=CC(N)=CC=N1 SVEQHRSELNPKJJ-UHFFFAOYSA-N 0.000 description 1
• QPEKEBRFZHIMMX-UHFFFAOYSA-N 2-methyl-1-(4-methylpiperidin-1-yl)propan-2-amine Chemical compound CC1CCN(CC(C)(C)N)CC1 QPEKEBRFZHIMMX-UHFFFAOYSA-N 0.000 description 1
• MWBKOGAZOXPSCI-UHFFFAOYSA-N 2-methyl-1-pyrrolidin-1-ylpropan-2-amine Chemical compound CC(C)(N)CN1CCCC1 MWBKOGAZOXPSCI-UHFFFAOYSA-N 0.000 description 1
• OWOUKRYOZIZVFK-UHFFFAOYSA-N 2-methylphenethylamine Chemical compound CC1=CC=CC=C1CCN OWOUKRYOZIZVFK-UHFFFAOYSA-N 0.000 description 1
• BVRDQVRQVGRNHG-UHFFFAOYSA-N 2-morpholin-4-ylpyrimido[2,1-a]isoquinolin-4-one Chemical compound N1=C2C3=CC=CC=C3C=CN2C(=O)C=C1N1CCOCC1 BVRDQVRQVGRNHG-UHFFFAOYSA-N 0.000 description 1
• LYGNMSMUTCMNQF-UHFFFAOYSA-N 2-pyridin-3-yloxypropan-1-amine Chemical compound NCC(C)OC1=CC=CN=C1 LYGNMSMUTCMNQF-UHFFFAOYSA-N 0.000 description 1
• FXIBFBGQYAPGLP-UHFFFAOYSA-N 2-pyridin-3-ylpropan-2-amine Chemical compound CC(C)(N)C1=CC=CN=C1 FXIBFBGQYAPGLP-UHFFFAOYSA-N 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• ZMBVBAVBXVSHER-UHFFFAOYSA-N 2-thiomorpholin-4-ylethanamine Chemical compound NCCN1CCSCC1 ZMBVBAVBXVSHER-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• GZZRWBRYYZGTNW-UHFFFAOYSA-N 3,5-dimethylpyrazin-2-amine Chemical compound CC1=CN=C(N)C(C)=N1 GZZRWBRYYZGTNW-UHFFFAOYSA-N 0.000 description 1
• DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
• VFTQRHWULYJKCI-UHFFFAOYSA-N 3-(1-adamantyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound C1CCCCN2C(C34CC5CC(C4)CC(C3)C5)=NN=C21 VFTQRHWULYJKCI-UHFFFAOYSA-N 0.000 description 1
• SRQRKYSRSKLMLW-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-8,9-diazatricyclo[4.3.0.02,4]nona-1(6),7-diene-7-carboxylic acid Chemical compound FC1=C(C=CC(=C1)F)C1C2C1CC=1C(=NNC2=1)C(=O)O SRQRKYSRSKLMLW-UHFFFAOYSA-N 0.000 description 1
• SJIFOHPZHHKGLQ-UHFFFAOYSA-N 3-(aminomethyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC(CN)=C1 SJIFOHPZHHKGLQ-UHFFFAOYSA-N 0.000 description 1
• QSPJOBDYLWKZPW-UHFFFAOYSA-N 3-(aminomethyl)-n,n-dimethylthiolan-3-amine Chemical compound CN(C)C1(CN)CCSC1 QSPJOBDYLWKZPW-UHFFFAOYSA-N 0.000 description 1
• SUDFIJJDSKVMSO-UHFFFAOYSA-N 3-(azepan-1-yl)-2,2-dimethylpropan-1-amine Chemical compound NCC(C)(C)CN1CCCCCC1 SUDFIJJDSKVMSO-UHFFFAOYSA-N 0.000 description 1
• SKMKJBYBPYBDMN-RYUDHWBXSA-N 3-(difluoromethoxy)-5-[2-(3,3-difluoropyrrolidin-1-yl)-6-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]pyridin-2-amine Chemical compound C1=C(OC(F)F)C(N)=NC=C1C1=CC(N2[C@H]3C[C@H](OC3)C2)=NC(N2CC(F)(F)CC2)=N1 SKMKJBYBPYBDMN-RYUDHWBXSA-N 0.000 description 1
• QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
• WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
• TZZDVPMABRWKIZ-MFTLXVFQSA-N 3-[6-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound OC=1C=C2CC[C@@H]([C@@H](C2=CC=1)C1=CC=C(C=C1)N1CCC(CC1)CN1CCN(CC1)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C1=CC=CC=C1 TZZDVPMABRWKIZ-MFTLXVFQSA-N 0.000 description 1
• CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 1
• COTHZSSUQJRBQH-UHFFFAOYSA-N 3-chloro-5-methylpyridin-2-amine Chemical compound CC1=CN=C(N)C(Cl)=C1 COTHZSSUQJRBQH-UHFFFAOYSA-N 0.000 description 1
• KJBKPRMEMJKXDV-UHFFFAOYSA-N 3-chloropyridin-4-amine Chemical compound NC1=CC=NC=C1Cl KJBKPRMEMJKXDV-UHFFFAOYSA-N 0.000 description 1
• WSAFCRLBAFJPTN-UHFFFAOYSA-N 3-cyclopentylpyridine Chemical compound C1CCCC1C1=CC=CN=C1 WSAFCRLBAFJPTN-UHFFFAOYSA-N 0.000 description 1
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
• WWEINXQNCAWBPD-UHFFFAOYSA-N 3-fluoropyridin-2-amine Chemical compound NC1=NC=CC=C1F WWEINXQNCAWBPD-UHFFFAOYSA-N 0.000 description 1
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
• JOZZAIIGWFLONA-UHFFFAOYSA-N 3-methylbutan-2-amine Chemical compound CC(C)C(C)N JOZZAIIGWFLONA-UHFFFAOYSA-N 0.000 description 1
• PDJZOFLRRJQYBF-UHFFFAOYSA-N 4-(aminomethyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C(CN)C=C1 PDJZOFLRRJQYBF-UHFFFAOYSA-N 0.000 description 1
• DLGZLIXYVSQGOX-UHFFFAOYSA-N 4-[8-[4-(4-tert-butylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]furan-2-carboxamide Chemical compound C1CN(C(C)(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=COC(C(N)=O)=C1 DLGZLIXYVSQGOX-UHFFFAOYSA-N 0.000 description 1
• WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
• MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
• XWQVQSXLXAXOPJ-QNGMFEMESA-N 4-[[[6-[5-chloro-2-[[4-[[(2r)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]pyridin-4-yl]pyridin-2-yl]amino]methyl]oxane-4-carbonitrile Chemical compound C1CC(N[C@H](C)COC)CCC1NC1=CC(C=2N=C(NCC3(CCOCC3)C#N)C=CC=2)=C(Cl)C=N1 XWQVQSXLXAXOPJ-QNGMFEMESA-N 0.000 description 1
• PUSZHIWAFZLOMD-UHFFFAOYSA-N 4-amino-2-methylbutan-2-ol Chemical compound CC(C)(O)CCN PUSZHIWAFZLOMD-UHFFFAOYSA-N 0.000 description 1
• GVCLNACSYKYUHP-UHFFFAOYSA-N 4-amino-7-(2-hydroxyethoxymethyl)pyrrolo[2,3-d]pyrimidine-5-carbothioamide Chemical compound C1=NC(N)=C2C(C(=S)N)=CN(COCCO)C2=N1 GVCLNACSYKYUHP-UHFFFAOYSA-N 0.000 description 1
• RNLRIDPDRLEOSF-UHFFFAOYSA-N 4-aminooxane-4-carbonitrile Chemical compound N#CC1(N)CCOCC1 RNLRIDPDRLEOSF-UHFFFAOYSA-N 0.000 description 1
• NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
• GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
• PVMNPAUTCMBOMO-UHFFFAOYSA-N 4-chloropyridine Chemical compound ClC1=CC=NC=C1 PVMNPAUTCMBOMO-UHFFFAOYSA-N 0.000 description 1
• DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
• 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
• 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• QPHBCOSULYSASF-UHFFFAOYSA-N 4-methoxypyridin-2-amine Chemical compound COC1=CC=NC(N)=C1 QPHBCOSULYSASF-UHFFFAOYSA-N 0.000 description 1
• 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
• PYSJLPAOBIGQPK-UHFFFAOYSA-N 4-phenyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1 PYSJLPAOBIGQPK-UHFFFAOYSA-N 0.000 description 1
• RSGVKIIEIXOMPY-UHFFFAOYSA-N 5-(trifluoromethyl)pyridin-2-amine Chemical compound NC1=CC=C(C(F)(F)F)C=N1 RSGVKIIEIXOMPY-UHFFFAOYSA-N 0.000 description 1
• FARGKMUKCFJLSU-VIFPVBQESA-N 5-[(2s)-1-methylpyrrolidin-2-yl]pyridin-2-amine Chemical compound CN1CCC[C@H]1C1=CC=C(N)N=C1 FARGKMUKCFJLSU-VIFPVBQESA-N 0.000 description 1
• VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
• KBLGGRWUEVCNPY-UHFFFAOYSA-N 5-bromo-3-methylpyridin-2-amine Chemical compound CC1=CC(Br)=CN=C1N KBLGGRWUEVCNPY-UHFFFAOYSA-N 0.000 description 1
• BSWOMKORDXSSKG-UHFFFAOYSA-N 5-bromo-3-tert-butyl-6-methyl-1h-pyrimidine-2,4-dione Chemical compound CC=1NC(=O)N(C(C)(C)C)C(=O)C=1Br BSWOMKORDXSSKG-UHFFFAOYSA-N 0.000 description 1
• XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
• YZSCPLGKKMSBMV-UHFFFAOYSA-N 5-fluoro-4-(8-fluoro-4-propan-2-yl-2,3-dihydro-1,4-benzoxazin-6-yl)-N-[5-(1-methylpiperidin-4-yl)pyridin-2-yl]pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)C1CCN(CC1)C)C1=CC2=C(OCCN2C(C)C)C(=C1)F YZSCPLGKKMSBMV-UHFFFAOYSA-N 0.000 description 1
• GUABFMPMKJGSBQ-UHFFFAOYSA-N 5-methyl-1,3-thiazol-2-amine Chemical compound CC1=CN=C(N)S1 GUABFMPMKJGSBQ-UHFFFAOYSA-N 0.000 description 1
• ZNQOALAKPLGUPH-UHFFFAOYSA-N 5-methylpyrazin-2-amine Chemical compound CC1=CN=C(N)C=N1 ZNQOALAKPLGUPH-UHFFFAOYSA-N 0.000 description 1
• CMBSSVKZOPZBKW-UHFFFAOYSA-N 5-methylpyridin-2-amine Chemical compound CC1=CC=C(N)N=C1 CMBSSVKZOPZBKW-UHFFFAOYSA-N 0.000 description 1
• IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
• 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
• RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
• IBOZOWZSXZNIHI-UHFFFAOYSA-N 6-(trifluoromethyl)pyridin-3-amine Chemical compound NC1=CC=C(C(F)(F)F)N=C1 IBOZOWZSXZNIHI-UHFFFAOYSA-N 0.000 description 1
• DMIHQARPYPNHJD-UHFFFAOYSA-N 6-amino-1h-pyridin-2-one Chemical compound NC1=CC=CC(O)=N1 DMIHQARPYPNHJD-UHFFFAOYSA-N 0.000 description 1
• GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
• UZALKVXCOUSWSL-UHFFFAOYSA-N 6-fluoropyridin-2-amine Chemical compound NC1=CC=CC(F)=N1 UZALKVXCOUSWSL-UHFFFAOYSA-N 0.000 description 1
• DEUALFRBMNMGDS-UHFFFAOYSA-N 6-methoxypyridin-2-amine Chemical compound COC1=CC=CC(N)=N1 DEUALFRBMNMGDS-UHFFFAOYSA-N 0.000 description 1
• UUVDJIWRSIJEBS-UHFFFAOYSA-N 6-methoxypyridin-3-amine Chemical compound COC1=CC=C(N)C=N1 UUVDJIWRSIJEBS-UHFFFAOYSA-N 0.000 description 1
• VELRBZDRGTVGGT-UHFFFAOYSA-N 6-methoxypyrimidin-4-amine Chemical compound COC1=CC(N)=NC=N1 VELRBZDRGTVGGT-UHFFFAOYSA-N 0.000 description 1
• NJIAKNWTIVDSDA-FQEVSTJZSA-N 7-[4-(1-methylsulfonylpiperidin-4-yl)phenyl]-n-[[(2s)-morpholin-2-yl]methyl]pyrido[3,4-b]pyrazin-5-amine Chemical compound C1CN(S(=O)(=O)C)CCC1C1=CC=C(C=2N=C(NC[C@H]3OCCNC3)C3=NC=CN=C3C=2)C=C1 NJIAKNWTIVDSDA-FQEVSTJZSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
• IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
• 206010006002 Bone pain Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
• ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
• BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 description 1
• JWCDFWJDYZIDHP-UHFFFAOYSA-N C=1C2=CC2=C2C(C(=O)O)=NNC2=1 Chemical compound C=1C2=CC2=C2C(C(=O)O)=NNC2=1 JWCDFWJDYZIDHP-UHFFFAOYSA-N 0.000 description 1
• SYZOFRXZMALRGI-JYJNAYRXSA-N CC1=C(NCC(F)(F)F)C(=O)N(C=C1)[C@@H](CC1CC1)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C#N Chemical compound CC1=C(NCC(F)(F)F)C(=O)N(C=C1)[C@@H](CC1CC1)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C#N SYZOFRXZMALRGI-JYJNAYRXSA-N 0.000 description 1
• UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
• BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
• SCJNYBYSTCRPAO-LXBQGUBHSA-N CN(C)C\C=C\C(=O)NC1=CC=C(N=C1)C(=O)N[C@@]1(C)CCC[C@H](C1)NC1=NC(C2=CNC3=CC=CC=C23)=C(Cl)C=N1 Chemical compound CN(C)C\C=C\C(=O)NC1=CC=C(N=C1)C(=O)N[C@@]1(C)CCC[C@H](C1)NC1=NC(C2=CNC3=CC=CC=C23)=C(Cl)C=N1 SCJNYBYSTCRPAO-LXBQGUBHSA-N 0.000 description 1
• VLASEIONQZWHSR-UHFFFAOYSA-N COC1=CC=C(C=C1)C1(CC1)NC(=O)C=1C2=CC=CC2=CC1 Chemical compound COC1=CC=C(C=C1)C1(CC1)NC(=O)C=1C2=CC=CC2=CC1 VLASEIONQZWHSR-UHFFFAOYSA-N 0.000 description 1
• PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 206010058019 Cancer Pain Diseases 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• RAPBNVDSDCTNRC-UHFFFAOYSA-N Chlorobenzilate Chemical compound C=1C=C(Cl)C=CC=1C(O)(C(=O)OCC)C1=CC=C(Cl)C=C1 RAPBNVDSDCTNRC-UHFFFAOYSA-N 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• BMNUEODJZRIPPI-UHFFFAOYSA-N ClNOC(=O)C1=CC=CC=C1 Chemical compound ClNOC(=O)C1=CC=CC=C1 BMNUEODJZRIPPI-UHFFFAOYSA-N 0.000 description 1
• 208000019399 Colonic disease Diseases 0.000 description 1
• 229940126657 Compound 17 Drugs 0.000 description 1
• 229940126639 Compound 33 Drugs 0.000 description 1
• 229940127007 Compound 39 Drugs 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
• 206010011796 Cystitis interstitial Diseases 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 description 1
• RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
• 206010061172 Gastrointestinal injury Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 1
• 101000875075 Homo sapiens Cannabinoid receptor 2 Proteins 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• 241000186660 Lactobacillus Species 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 101100434906 Mus musculus Angptl8 gene Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000007101 Muscle Cramp Diseases 0.000 description 1
• 208000008238 Muscle Spasticity Diseases 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
• GPAUKUWZNAEPNY-CYBMUJFWSA-N N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]pentalene-1-carboxamide Chemical compound CC([C@@H](C(NC)=O)NC(=O)C=1C2=CC=CC2=CC=1)(C)C GPAUKUWZNAEPNY-CYBMUJFWSA-N 0.000 description 1
• LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 1
• CLCTZVRHDOAUGJ-UHFFFAOYSA-N N-[4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-[[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperazin-1-yl]methyl]piperidin-1-yl]pyridazine-3-carboxamide Chemical compound FC1=CC2=C(C=C1N1CCN(CC3CCN(CC3)C3=CC=C(N=N3)C(=O)NC3CCC(CC3)OC3=CC(Cl)=C(C=C3)C#N)CC1)C(=O)N(C1CCC(=O)NC1=O)C2=O CLCTZVRHDOAUGJ-UHFFFAOYSA-N 0.000 description 1
• AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
• POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
• ONPLGUXXFZRFMJ-UHFFFAOYSA-N N-cyclopentylpentalene-1-carboxamide Chemical compound C1CCC(C1)NC(=O)C2=C3C=CC=C3C=C2 ONPLGUXXFZRFMJ-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• GGHJSXZWNLNXFL-UHFFFAOYSA-N N-tert-butyl-2,2-dimethyl-1-pyridin-2-ylpropan-1-amine Chemical compound CC(C)(C)C(C1=CC=CC=N1)NC(C)(C)C GGHJSXZWNLNXFL-UHFFFAOYSA-N 0.000 description 1
• OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
• QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 206010065673 Nephritic syndrome Diseases 0.000 description 1
• 208000001294 Nociceptive Pain Diseases 0.000 description 1
• VWQGOQSMLIKZKR-UHFFFAOYSA-N O1C(C)=NC(C2(N)CCCCC2)=N1 Chemical compound O1C(C)=NC(C2(N)CCCCC2)=N1 VWQGOQSMLIKZKR-UHFFFAOYSA-N 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
• 206010061481 Renal injury Diseases 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 206010038678 Respiratory depression Diseases 0.000 description 1
• 208000008765 Sciatica Diseases 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 206010041349 Somnolence Diseases 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000002847 Surgical Wound Diseases 0.000 description 1
• 206010043087 Tachyphylaxis Diseases 0.000 description 1
• NBQCNZYJJMBDKY-UHFFFAOYSA-N Terbacil Chemical compound CC=1NC(=O)N(C(C)(C)C)C(=O)C=1Cl NBQCNZYJJMBDKY-UHFFFAOYSA-N 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
• 206010057362 Underdose Diseases 0.000 description 1
• HQVHOQAKMCMIIM-HXUWFJFHSA-N WIN 55212-2 Chemical compound C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 HQVHOQAKMCMIIM-HXUWFJFHSA-N 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
• SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
• DRBWRJPFNOBNIO-KOLCDFICSA-N [(2r)-1-[(2r)-2-(pyridine-4-carbonylamino)propanoyl]pyrrolidin-2-yl]boronic acid Chemical compound N([C@H](C)C(=O)N1[C@@H](CCC1)B(O)O)C(=O)C1=CC=NC=C1 DRBWRJPFNOBNIO-KOLCDFICSA-N 0.000 description 1
• LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
• YGPZYYDTPXVBRA-RTDBHSBRSA-N [(2r,3s,4r,5r,6s)-2-[[(2r,3r,4r,5s,6r)-3-[[(3r)-3-dodecanoyloxytetradecanoyl]amino]-6-(hydroxymethyl)-5-phosphonooxy-4-[(3r)-3-tetradecanoyloxytetradecanoyl]oxyoxan-2-yl]oxymethyl]-3,6-dihydroxy-5-[[(3r)-3-hydroxytetradecanoyl]amino]oxan-4-yl] (3r)-3-hydr Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](O)O1 YGPZYYDTPXVBRA-RTDBHSBRSA-N 0.000 description 1
• PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
• DVRUPOLTRICBFA-UHFFFAOYSA-N [1-(2-methoxyethyl)piperidin-4-yl]methanamine Chemical compound COCCN1CCC(CN)CC1 DVRUPOLTRICBFA-UHFFFAOYSA-N 0.000 description 1
• TUPUHSXMDIWJQT-UHFFFAOYSA-N [3-(trifluoromethoxy)phenyl]methanamine Chemical compound NCC1=CC=CC(OC(F)(F)F)=C1 TUPUHSXMDIWJQT-UHFFFAOYSA-N 0.000 description 1
• UHWPLNHRROQPMB-UHFFFAOYSA-N [4-(difluoromethoxy)phenyl]methanamine Chemical compound NCC1=CC=C(OC(F)F)C=C1 UHWPLNHRROQPMB-UHFFFAOYSA-N 0.000 description 1
• SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 210000003489 abdominal muscle Anatomy 0.000 description 1
• 210000003815 abdominal wall Anatomy 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 229960000583 acetic acid Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
• LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000003502 anti-nociceptive effect Effects 0.000 description 1
• 210000000742 appendix Anatomy 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000013011 aqueous formulation Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
• SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 1
• 230000006793 arrhythmia Effects 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 235000021311 artificial sweeteners Nutrition 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
• OTKPPUXRIADSGD-PPRNARJGSA-N avoparcina Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2C([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)OC2=CC=C(C=C2)[C@@H](O)[C@H](C(N[C@H](C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](NC)C=1C=CC(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)=CC=1)[C@H]1C[C@@H](N)[C@@H](O)[C@H](C)O1 OTKPPUXRIADSGD-PPRNARJGSA-N 0.000 description 1
• JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
• YWCASUPWYFFUHE-UHFFFAOYSA-N bis(3-methylsulfonyloxypropyl)azanium;chloride Chemical compound [Cl-].CS(=O)(=O)OCCC[NH2+]CCCOS(C)(=O)=O YWCASUPWYFFUHE-UHFFFAOYSA-N 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229950011318 cannabidiol Drugs 0.000 description 1
• QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
• ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 1
• 239000003520 cannabinoid receptor affecting agent Substances 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 239000000679 carrageenan Substances 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 229920001525 carrageenan Polymers 0.000 description 1
• 229940113118 carrageenan Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 230000000112 colonic effect Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000000306 component Substances 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 229940125773 compound 10 Drugs 0.000 description 1
• 229940125797 compound 12 Drugs 0.000 description 1
• 229940126543 compound 14 Drugs 0.000 description 1
• 229940125758 compound 15 Drugs 0.000 description 1
• 229940126142 compound 16 Drugs 0.000 description 1
• 229940125782 compound 2 Drugs 0.000 description 1
• 229940125810 compound 20 Drugs 0.000 description 1
• 229940126086 compound 21 Drugs 0.000 description 1
• 229940126208 compound 22 Drugs 0.000 description 1
• 229940125833 compound 23 Drugs 0.000 description 1
• 229940125961 compound 24 Drugs 0.000 description 1
• 229940125846 compound 25 Drugs 0.000 description 1
• 229940125851 compound 27 Drugs 0.000 description 1
• 229940127204 compound 29 Drugs 0.000 description 1
• 229940126214 compound 3 Drugs 0.000 description 1
• 229940125877 compound 31 Drugs 0.000 description 1
• 229940125878 compound 36 Drugs 0.000 description 1
• 229940125807 compound 37 Drugs 0.000 description 1
• 229940127573 compound 38 Drugs 0.000 description 1
• 229940126540 compound 41 Drugs 0.000 description 1
• 229940125936 compound 42 Drugs 0.000 description 1
• 229940125844 compound 46 Drugs 0.000 description 1
• 229940127271 compound 49 Drugs 0.000 description 1
• 229940125898 compound 5 Drugs 0.000 description 1
• 229940126545 compound 53 Drugs 0.000 description 1
• 229940127113 compound 57 Drugs 0.000 description 1
• 229940125900 compound 59 Drugs 0.000 description 1
• 229940126179 compound 72 Drugs 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• DFBKLUNHFCTMDC-PICURKEMSA-N dieldrin Chemical compound C([C@H]1[C@H]2[C@@]3(Cl)C(Cl)=C([C@]([C@H]22)(Cl)C3(Cl)Cl)Cl)[C@H]2[C@@H]2[C@H]1O2 DFBKLUNHFCTMDC-PICURKEMSA-N 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
• QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
• BFXLJWUGRPGMFU-UHFFFAOYSA-N dipropoxyphosphinothioyl n,n-diethylcarbamodithioate;sulfane Chemical compound S.CCCOP(=S)(OCCC)SC(=S)N(CC)CC BFXLJWUGRPGMFU-UHFFFAOYSA-N 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• DFBKLUNHFCTMDC-GKRDHZSOSA-N endrin Chemical compound C([C@@H]1[C@H]2[C@@]3(Cl)C(Cl)=C([C@]([C@H]22)(Cl)C3(Cl)Cl)Cl)[C@@H]2[C@H]2[C@@H]1O2 DFBKLUNHFCTMDC-GKRDHZSOSA-N 0.000 description 1
• BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
• 210000005216 enteric neuron Anatomy 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
• 125000004494 ethyl ester group Chemical group 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000008622 extracellular signaling Effects 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 108010046094 fatty-acid amide hydrolase Proteins 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 125000001207 fluorophenyl group Chemical group 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• CUTZNERBKDMLAP-UHFFFAOYSA-N gtpl5785 Chemical compound C1C2=C(C(=O)O)NN=C2C2CC21 CUTZNERBKDMLAP-UHFFFAOYSA-N 0.000 description 1
• JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 102000056693 human CNR2 Human genes 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 239000005414 inactive ingredient Substances 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• QBYJBZPUGVGKQQ-DIFDVCDBSA-N isodrin Chemical compound C1[C@@H]2C=C[C@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-DIFDVCDBSA-N 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 208000037806 kidney injury Diseases 0.000 description 1
• 229940039696 lactobacillus Drugs 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• MKQLBNJQQZRQJU-UHFFFAOYSA-N morpholin-4-amine Chemical compound NN1CCOCC1 MKQLBNJQQZRQJU-UHFFFAOYSA-N 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 208000013465 muscle pain Diseases 0.000 description 1
• YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
• IHCHOVVAJBADAH-UHFFFAOYSA-N n-[2-hydroxy-4-(1h-pyrazol-4-yl)phenyl]-6-methoxy-3,4-dihydro-2h-chromene-3-carboxamide Chemical compound C1C2=CC(OC)=CC=C2OCC1C(=O)NC(C(=C1)O)=CC=C1C=1C=NNC=1 IHCHOVVAJBADAH-UHFFFAOYSA-N 0.000 description 1
• YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
• LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 235000021096 natural sweeteners Nutrition 0.000 description 1
• IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
• 210000001640 nerve ending Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 108091008700 nociceptors Proteins 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• YNOGYQAEJGADFJ-UHFFFAOYSA-N oxolan-2-ylmethanamine Chemical compound NCC1CCCO1 YNOGYQAEJGADFJ-UHFFFAOYSA-N 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 229940124641 pain reliever Drugs 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 210000001986 peyer's patch Anatomy 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 239000006041 probiotic Substances 0.000 description 1
• 230000000529 probiotic effect Effects 0.000 description 1
• 235000018291 probiotics Nutrition 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 239000011241 protective layer Substances 0.000 description 1
• 230000000506 psychotropic effect Effects 0.000 description 1
• 230000000541 pulsatile effect Effects 0.000 description 1
• DXBWJLDFSICTIH-UHFFFAOYSA-N pyrazine-2-carbaldehyde Chemical compound O=CC1=CN=CC=N1 DXBWJLDFSICTIH-UHFFFAOYSA-N 0.000 description 1
• LETVJWLLIMJADE-UHFFFAOYSA-N pyridazin-3-amine Chemical compound NC1=CC=CN=N1 LETVJWLLIMJADE-UHFFFAOYSA-N 0.000 description 1
• TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 1
• LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
• OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 1
• SBMSLRMNBSMKQC-UHFFFAOYSA-N pyrrolidin-1-amine Chemical compound NN1CCCC1 SBMSLRMNBSMKQC-UHFFFAOYSA-N 0.000 description 1
• BVQGQPVMVBOTID-UHFFFAOYSA-N quinolin-4-ylmethanamine Chemical compound C1=CC=C2C(CN)=CC=NC2=C1 BVQGQPVMVBOTID-UHFFFAOYSA-N 0.000 description 1
• 238000003653 radioligand binding assay Methods 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 230000020341 sensory perception of pain Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 210000001599 sigmoid colon Anatomy 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
• AGDSCTQQXMDDCV-UHFFFAOYSA-M sodium;2-iodoacetate Chemical compound [Na+].[O-]C(=O)CI AGDSCTQQXMDDCV-UHFFFAOYSA-M 0.000 description 1
• 208000018198 spasticity Diseases 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 201000009032 substance abuse Diseases 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• RPIXOLUIHUFDOY-UHFFFAOYSA-N thian-4-amine Chemical compound NC1CCSCC1 RPIXOLUIHUFDOY-UHFFFAOYSA-N 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 208000004371 toothache Diseases 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
• WRPWWVNUCXQDQV-UHFFFAOYSA-N vanillylamine Chemical compound COC1=CC(CN)=CC=C1O WRPWWVNUCXQDQV-UHFFFAOYSA-N 0.000 description 1
• 210000004760 visceral afferent Anatomy 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• 239000011345 viscous material Substances 0.000 description 1
• 230000001755 vocal effect Effects 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1